Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Effectiveness of CRD-740 in Heart Failure

ClinicalTrials.gov ID: NCT05409183

Public ClinicalTrials.gov record NCT05409183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)

Study identification

NCT ID
NCT05409183
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Enrollment
60 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 25, 2022
Primary completion
May 1, 2023
Completion
Jul 24, 2023
Last update posted
Dec 18, 2024

2022 – 2023

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Cardurion Investigative Site Alexander City Alabama 35010
Cardurion Investigative Site Birmingham Alabama 35211
Cardurion Investigative Site Fairhope Alabama 36532
Cardurion Investigative Site Torrance California 90502
Cardurion Investigative Site Hialeah Florida 33016
Cardurion Investigative Site Miami Florida 33133
Cardurion Investigative Site Miami Florida 33169
Cardurion Investigative Site Naples Florida 34102
Cardurion Investigative Site Tampa Florida 33612
Cardurion Investigative Site Atlanta Georgia 30303
Cardurion Investigative Site Hazel Crest Illinois 60429
Cardurion Investigative Site Alexandria Louisiana 71301
Cardurion Investigative Site Minneapolis Minnesota 55415
Cardurion Investigative Site Greensboro North Carolina 27408
Cardurion Investigative Site Tullahoma Tennessee 37388
Cardurion Investigative Site Allen Texas 75013
Cardurion Investigative Site Norfolk Virginia 23504

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05409183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05409183 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →